Charlotte F. McDonagh

Antitumor Activity of a Novel Bispecific Antibody That Targets the ErbB2/ErbB3 Oncogenic Unit and Inhibits Heregulin-Induced Activation of ErbB3

Charlotte F. McDonagh, Alexandra Huhalov, Brian D. Harms et al. · Molecular Cancer Therapeutics · 2012 · 274 citations · Full text

Breast Oncology, Antitumor Activity, Immunology +18

Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment

Charlotte F. McDonagh, Eileen Turcott, Lori Westendorf et al. · Protein Engineering Design and Selection · 2006 · 236 citations · Full text

Medicinal Chemistry, Parental Antibody-drug Conjugates, Medicine +15

Computational Modeling of <i>ERBB2</i> -Amplified Breast Cancer Identifies Combined ErbB2/3 Blockade as Superior to the Combination of MEK and AKT Inhibitors

Daniel C. Kirouac, Jin Du, Johanna Lahdenranta et al. · Science Signaling · 2013 · 107 citations

Single-Cell Quantitative HER2 Measurement Identifies Heterogeneity and Distinct Subgroups within Traditionally Defined HER2-Positive Patients

Matthew Onsum, Elena Geretti, Violette Paragas et al. · American Journal Of Pathology · 2013 · 105 citations · Full text

Medicine, Pathology, Her2-positive Patients +5

Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities

Julie A. McEarchern, Ezogelin Oflazoglu, Leigh Francisco et al. · Blood · 2006 · 100 citations · Full text